Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Executive Summary
Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.
You may also be interested in...
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: